Company Profile

Iron Horse Diagnostics Inc
Profile last edited on: 5/13/19      CAGE: 6S9G2      UEI:

Business Identifier: Diagnostic and prognostic tests for neurologic diseases, including ALS.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

21053 N 75th Street
Scottsdale, AZ 85255
   (602) 810-0812
Location: Single
Congr. District: 06
County: Maricopa

Public Profile

Iron Horse Diagnostics, Inc. is a molecular diagnostic company focused on the development and commercialization of novel tests to support the diagnosis and management of amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI), and other neurological diseases. The firm has developed and validated assays to measure protein-based signatures of disease. The company is developing diagnostics for ALS based on cerebrospinal fluid samples. In addition, the company is researching a blood-based diagnostic for ALS, with additional prognostic assays for ALS that can be used to monitor disease progression and test the effectiveness of drugs in clinical trials. Follow-up blood-based diagnostic assays will be for TBI and neuronal injury. ALS is currently clinically diagnosed by ruling out all other diseases that may cause symptoms similar to those presented by the patient. Iron Horse is developing the first diagnostic test for ALS that will rapidly determine if someone has the disease. Iron Horse is also developing markers of disease progression that will be useful to monitor disease progression and drug treatments during clinical trials.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 2 NIH $1,121,400
Project Title: Commercialization of a Diagnostic Test for Amyotrophic Lateral Sclerosis (ALS)

Key People / Management

  Robert P Bowser -- President and CEO

  Andreas Jeromin -- Chief Scientific Officer

  Gerry Shaw -- Co-Founder and Scientific Advisor